^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Perjeta (pertuzumab) (HER2 dimerization inhibitor) + Cipterbin (inetetamab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer
Excerpt:
...- HER2-positive: an immunohistochemistry (IHC) score of 3+ or IHC 2+ and in situ hybridization ISH+/fluorescence in situ hybridization FISH+....
Trial ID:
Source:
Title:
Inetetamab Combined with Pertuzumab and Docetaxel for the Neoadjuvant Therapy of HER-2 positive breast cancer: a Single-arm Phase II Study.
Excerpt:
......
Trial ID:
Less C2 evidence
Source:
Title:
Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab, Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer
Published date:
12/02/2023
Excerpt:
Neoadjuvant therapy with TCbIP demonstrated promising efficacy and manageable toxicity in patients with HER2-positive locally advanced breast cancer.
Secondary therapy:
carboplatin + paclitaxel
Trial ID:
Source:
Title:
360P - Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study
Published date:
10/16/2023
Excerpt:
The ORR was 91.3% (21/23) in the ITT population and 93.8% (15/16) in the PP population. Among the 16 patients in the PP population, 10 patients (62.5%) achieved pCR. A total of 14 patients (87.5%) achieved npCR….Neoadjuvant therapy with TCbIP has shown promising efficacy and manageable toxicity in patients with HER2-positive LA breast cancer.
Secondary therapy:
carboplatin + paclitaxel
Source:
Title:
Neoadjuvant inetetamab combined with pertuzumab, paclitaxel, and carboplatin (TCbIP) for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study.
Published date:
05/25/2023
Excerpt:
This phase II trial included patients with histologically confirmed stage IIA to IIIC HER2-positive primary invasive breast cancer. Eligible patients receive TCbIP treatment...ORR was achieved 78.9% in the ITT population (15 of 19 patients) and 91.7% in the PP population (11 of 12 patients). Among 12 patients of PP population, 8 patients (66.7%) achieved pCR and 10 patients (83.3%) achieved npCR...TCbIP displays a promising efficacy (pCR rate of 66.7%) and manageable toxicity in patients with HER2-positive LA breast cancer in the neoadjuvant setting.
Secondary therapy:
carboplatin + paclitaxel
DOI:
10.1200/JCO.2023.41.16_suppl.e12597
Trial ID:
